Cancer Rop Co. Ltd. Net Assets
Cancer Rop Co. Ltd. net assets. Based on the latest financial reports, Cancer Rop Co. Ltd. (180400) has net assets worth ₩90.79 Billion KRW (≈ $61.53 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩115.39 Billion ≈ $78.20 Million USD) and total liabilities (₩24.60 Billion ≈ $16.67 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Cancer Rop Co. Ltd. to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩90.79 Billion |
| % of Total Assets | 78.68% |
| Annual Growth Rate | 26.55% |
| 5-Year Change | 174.36% |
| 10-Year Change | N/A |
| Growth Volatility | 166.52 |
Net Assets of Cancer Rop Co. Ltd. (2014–2025)
Net assets of Cancer Rop Co. Ltd. from 2014 to 2025. This chart illustrates how Cancer Rop Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. See Cancer Rop Co. Ltd. net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Cancer Rop Co. Ltd. (2014–2025)
The table below shows the annual net assets of Cancer Rop Co. Ltd. from 2014 to 2025. For live market cap and overall valuation, see 180400 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩95.76 Billion ≈ $64.90 Million |
+485.56% |
| 2024-12-31 | ₩16.35 Billion ≈ $11.08 Million |
-43.21% |
| 2023-12-31 | ₩28.80 Billion ≈ $19.51 Million |
-16.17% |
| 2022-12-31 | ₩34.35 Billion ≈ $23.28 Million |
-1.59% |
| 2018-12-31 | ₩34.91 Billion ≈ $23.65 Million |
+0.45% |
| 2017-12-31 | ₩34.75 Billion ≈ $23.55 Million |
+19.61% |
| 2016-12-31 | ₩29.05 Billion ≈ $19.69 Million |
+34.76% |
| 2015-12-31 | ₩21.56 Billion ≈ $14.61 Million |
+200.17% |
| 2014-12-31 | ₩7.18 Billion ≈ $4.87 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cancer Rop Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14925101167000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Cancer Rop Co. Ltd. Net Assets Breakdown (December 2025)
Cancer Rop Co. Ltd. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩244.87 Billion | 260.65% |
| Total Equity | ₩93.95 Billion | 100.00% |
Cancer Rop Co. Ltd. Competitors by Market Cap
The table below lists competitors of Cancer Rop Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
STLLR Gold Inc.
TO:STLR
|
$121.41 Million |
|
Caisse Regionale De Credit Agricole Mutuel Sud Rhone Alpes
PA:CRSU
|
$121.41 Million |
|
Thai Steel Cable Public Company Limited
BK:TSC
|
$121.47 Million |
|
Severn Trent PLC
LSE:SVT
|
$121.51 Million |
|
Atlas Salt Inc
V:SALT
|
$121.40 Million |
|
RumbleON Inc
NASDAQ:RMBL
|
$121.37 Million |
|
John Hancock Income Securities Closed Fund
NYSE:JHS
|
$121.36 Million |
|
Joyce Corporation Ltd
AU:JYC
|
$121.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cancer Rop Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,970,370,280 to 93,945,159,330, a change of 79,974,789,050 (572.5%).
- Net loss of 29,039,291,560 reduced equity.
- New share issuances of 99,609,704,000 increased equity.
- Other factors increased equity by 9,404,376,610.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-29.04 Billion | -30.91% |
| Share Issuances | ₩99.61 Billion | +106.03% |
| Other Changes | ₩9.40 Billion | +10.01% |
| Total Change | ₩- | 572.46% |
Book Value vs Market Value Analysis
This analysis compares Cancer Rop Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.91x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.54x to 1.91x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩1184.10 | ₩1820.00 | x |
| 2023-12-31 | ₩700.68 | ₩1820.00 | x |
| 2024-12-31 | ₩283.84 | ₩1820.00 | x |
| 2025-12-31 | ₩954.45 | ₩1820.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cancer Rop Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -30.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -98.92%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.65x
- Recent ROE (-30.91%) is above the historical average (-57.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 2.90% | 4.44% | 0.61x | 1.07x | ₩-510.13 Million |
| 2015 | 2.85% | 11.42% | 0.24x | 1.03x | ₩-1.54 Billion |
| 2016 | -1.65% | -9.41% | 0.17x | 1.02x | ₩-3.38 Billion |
| 2017 | -6.27% | -46.64% | 0.08x | 1.65x | ₩-5.65 Billion |
| 2018 | -15.37% | -71.44% | 0.11x | 1.94x | ₩-8.86 Billion |
| 2022 | -2.29% | -2.42% | 0.37x | 2.53x | ₩-4.18 Billion |
| 2023 | -129.79% | -66.63% | 0.41x | 4.72x | ₩-29.60 Billion |
| 2024 | -336.67% | -138.55% | 0.47x | 5.18x | ₩-48.43 Billion |
| 2025 | -30.91% | -98.92% | 0.19x | 1.65x | ₩-38.43 Billion |
Industry Comparison
This section compares Cancer Rop Co. Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $94,427,609,630
- Average return on equity (ROE) among peers: -22.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cancer Rop Co. Ltd. (180400) | ₩90.79 Billion | 2.90% | 0.27x | $121.40 Million |
| NSN Co. Ltd (031860) | $51.00 Billion | -27.70% | 0.20x | $12.68 Million |
| JOONGANG DNM Co.Ltd (051980) | $42.13 Billion | -34.73% | 0.45x | $498.88 Million |
| GeneMatrix Inc (109820) | $10.83 Billion | -28.68% | 1.91x | $18.98 Million |
| Genoray Co. Ltd (122310) | $95.53 Billion | 13.07% | 0.30x | $24.78 Million |
| Green Cross Lab Cell Corporation (144510) | $511.00 Billion | 6.15% | 0.26x | $102.86 Million |
| Optipharm.CO.LTD (153710) | $13.50 Billion | -2.58% | 0.52x | $42.20 Million |
| Cytogen Inc (217330) | $17.92 Billion | -23.11% | 0.10x | $36.19 Million |
| Gencurix Inc (229000) | $30.99 Billion | -111.87% | 0.78x | $31.07 Million |
| P&K Skin Research Center Co. Ltd (347740) | $76.94 Billion | 7.56% | 0.07x | $35.45 Million |
About Cancer Rop Co. Ltd.
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services;… Read more